Clinical trials: Systemic Lupus
Juvenile Systemic Lupus Erythematosus
AS-OCT Study of Cornea and Tear Film Parameters in Juvenile SLE Patients
The aim of thie study to assess tear film parameters such as tear meniscus height (TMH), tear meniscus area (TMA), and tear meniscus depth (TMD).
- Trial name
- NCT05015465
- Testing
- Anterior Segment OCT
- Where
- Egypt
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Minia University
Lupus Nephritis
Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis
In this study, we aimed to evaluate the long term efficacy, remission, survival and safety of autologous hematopoietic stem cell transplantation in patients with refractory lupus nephritis.
- Trial name
- NCT03828071
- Testing
- Autologous hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Nanjing University School of Medicine
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases
This study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants…
- Trial name
- NCT07751315
- Testing
- Ia:QLS2404 very low dose, Ia:QLS2404 low dose, Ia:QLS2404 middle dose
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Systemic Lupus Erthematosus, Lupus Glomerulonephritis
Renal Resistive Index as an Indicator of Lupus Nephritis Severity and Systemic Lupus Activity
The study explores the role of the colour Doppler scanning of the renal arteries and its relation to the degree of disease affection in lupus nephritis
- Conditions
- Systemic Lupus Erthematosus, Lupus Glomerulonephritis, Lupus Flare
- Trial name
- NCT06757725
- Testing
- colour doppler of the renal artery and measurement of resistive index
- Where
- Egypt
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Kasr El Aini Hospital
Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis
To demonstrate that the treatment effect in lupus nephritis of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.
- Trial name
- NCT02256150
- Testing
- Mizoribine (MZR), Cyclophosphamide (CTX)
- Where
- 26 sites in China
- Volunteers
- 250 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Systemic Lupus Erythematosus, Lupus Erythematosus
A Study of Imvotamab in Severe Systemic Lupus Erythematosus
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with severe systemic lupus erythematosus who have failed prior therapies.
- Trial name
- NCT06041568
- Testing
- Imvotamab
- Where
- 10 sites in United States, Poland and 1 more
- Volunteers
- 17 people
- Sponsor
- IGM Biosciences, Inc.
Lupus Nephritis
Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis
The purpose of this study is to assess the efficacy and safety of multi-target therapy in the treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ lupus nephritis.
- Trial name
- NCT00876616
- Testing
- Tacrolimus+Mycophenolate mofetil, Cyclophosphamide
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Zhi-Hong Liu, M.D.
System; Lupus Erythematosus, Cognition Disorder
Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune and inflammatory disease. The pathogenesis of SLE results from interactions between genes, hormones, and the environment; however, the exact etiology is unknown.
- Conditions
- System; Lupus Erythematosus, Cognition Disorder, Autoimmune
- Trial name
- NCT05984316
- Testing
- Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Biruni University
Lupus Erythematosus, Systemic
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies and accumulation of immune complexes resulting in systemic inflammatory response and tissue damage.
- Trial name
- DYSALARM-322 (NCT05193591)
- Testing
- Autoantibodies evaluation in lupus
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Grenoble
Systemic Lupus Erythematosus (SLE)
A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of TJ202 in Patients with Systemic Lupus…
- Trial name
- NCT05140824
- Testing
- TJ202 injection
- Where
- 2 sites in China
- Volunteers
- 1 people
- Sponsor
- TJ Biopharma Co., Ltd.
Depression, Anxiety
Web-based CBT for Symptoms of Mild-to-Moderate Anxiety and Depression in Youth With Chronic Illness
Symptoms of anxiety and depression are common in adolescents and young adults with chronic illnesses and are associated with decreased adherence to medical regimens.
- Conditions
- Depression, Anxiety, Inflammatory Bowel Disease, Systemic Lupus Erythematosus
- Trial name
- NCT02453880
- Testing
- Web-based Cognitive Behavioral Therapy
- Volunteers
- 14 people
- Sponsor
- Stanford University
Healthy Volunteers, Rheumatoid Arthritis
A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.
- Conditions
- Healthy Volunteers, Rheumatoid Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT06917742
- Testing
- CPTX2309
- Where
- 3 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Capstan Therapeutics
Systemic Lupus Erythematosus
Effects of Treatment of Chronic Stress in Patients With Lupus
Daily stress can worsens the clinical course of lupus. Objective: to determine the efficacy of the stress management therapy in a group of patients with lupus.
- Trial name
- NCT00483613
- Testing
- Cognitive-behavioral therapy of Meichenbaum
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- University Hospital Virgen de las Nieves
Systemic Lupus Erthematosus
Bone Mineral Density in Patients With Childhood-onset Systemic Lupus Erythematous, in Relation to Disease Clinical Criteria
To determine the most common clinical characteristics in patients with childhood -onset systemic lupus erythematosus. To detect prevalence of low bone mineral density in patients with childhood -onset systemic lupus erythematosus.
- Trial name
- NCT06586359
- Volunteers
- 78 people
- Sponsor
- Assiut University
Systemic Lupus Erthematosus, Fatigue
Home-Based High-Intensity Interval Training in Systemic Lupus Erythematosus
Systemic lupus erythematosus, or SLE, is a chronic autoimmune disease that can cause persistent fatigue, muscle pain, reduced physical function, and impaired quality of life, even when the disease is otherwise clinically stable.
- Conditions
- Systemic Lupus Erthematosus, Fatigue, Exercise Training
- Trial name
- MIGHT-SLE (NCT07716462)
- Testing
- Personalized Home-Based High-Intensity Interval Training
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Systemic Lupus Erythematosus, Chronic Headache
The Effectiveness of Transcranial Direct Current Stimulation as Adjunctive Treatment for Chronic Daily Headache in Systemic Lupus Erythematosus
The prevalence of chronic primary headache in Systemic Lupus Erythematosus (SLE) is 54.4%. Several studies have shown that the use of transcranial direct current stimulation (tDCS) at the primary motor cortex (M1), primary…
- Trial name
- SHADE (NCT05613582)
- Testing
- Transcranial Direct Current Stimulation
- Volunteers
- 88 people
- Sponsor
- Universitas Indonesia
Relapsed/Refractory Autoimmune Diseases
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases
This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory autoimmune diseases.
- Trial name
- NCT06866080
- Testing
- LCAR-AIO T cells
- Where
- 4 sites in China
- Sponsor
- Nanjing Legend Biotech Co.
Lupus Nephritis (LN), Lupus Nephritis - WHO Class III
Safety and Efficacy of ONT01 in Lupus
ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA.
- Conditions
- Lupus Nephritis (LN), Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Lupus Nephritis - World Health Organization (WHO) Class III
- Trial name
- NCT07107659
- Testing
- ONT01 is a small molecule CD11b modulator.
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Hospital for Special Surgery, New York
Lupus Nephritis
Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the…
- Trial name
- NCT02770170
- Testing
- BI 655064 dose 1, BI 655064 dose 2, BI 655064 dose 3
- Where
- 74 sites in United States, Australia and 18 more
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.